
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
Oncology Institute is well-positioned for success in the healthcare industry due to their optimized workflows and potential for growth in their Specialty Pharmacy segment. Their strong cost management and expansion plans make them a promising investment, but competition and debt may pose risks. With positive results expected from current initiatives and a rapidly growing oncology market, their stock has the potential to rise above the current price of $9.
Bears say
Oncology Institute is predicted to outperform FY26 guidance and achieve high single-digit EBITDA margins by 2028 through the launch of a provider portal and increasing its capitated contracts. However, the lack of contribution from net new wins in FY26 may hinder its potential for higher dispensary revenue and there is a risk of increased competition from other healthcare providers. The current valuation at EV/0.6x 2027 estimated revenue suggests an undervaluation for TOI compared to its peers, but there are risks associated with medical costs and potential limitations for future growth.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares